Increased levels of 5‐HT1A receptor binding in ventral visual pathways in Parkinson's disease

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Movement Disorders

• Publication date

  2012-05-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1002/mds.24964PMID 22419526
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque.

  2012cited by this paper
• Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson's disease

  2012cited by this paper
• Role of the primary motor cortex in L-Dopa-induced dyskinesia and its modulation by 5-HT1A receptor stimulation.

  2011cited by this paper
• The serotonergic system in Parkinson's disease.

  2011cited by this paper
• Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats.

  2011cited by this paper
• Relationships between age and late progression of Parkinson's disease: a clinico-pathological study.

  2010cited by this paper
• Increased 5‐HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations

  2010cited by this paper
• Serotonin 2A receptors and visual hallucinations in Parkinson disease.

  2010cited by this paper
• The role of the dorsal raphe nucleus in the development, expression, and treatment of L‐dopa‐induced dyskinesia in hemiparkinsonian rats

  2009cited by this paper
• Serotonin and Parkinson's disease: On movement, mood, and madness

  2009cited by this paper
• L-Dopa treatment abolishes the numerical increase in striatal dopaminergic neurons in parkinsonian monkeys.

  2008cited by this paper
• Cortical Serotonin 1A Receptor Levels Are Associated with Depression in Patients with Dementia with Lewy Bodies and Parkinson’s Disease Dementia

  2008cited by this paper
• Circuits and circuit disorders of the basal ganglia.

  2007cited by this paper
• Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.

  2007cited by this paper
• The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.

  2006cited by this paper
• WAY-100635 is a potent dopamine D4 receptor agonist

  2006cited by this paper
• A review of the receptor-binding and pharmacokinetic properties of dopamine agonists.

  2006cited by this paper
• 2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole (A-381393), a selective dopamine D4 receptor antagonist.

  2005cited by this paper
• Increased D1 dopamine receptor signaling in levodopa‐induced dyskinesia

  2005cited by this paper
• Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia.

  2005cited by this paper
• Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 years

  2005cited by this paper
• Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study.

  2005cited by this paper
• Role of Inflammation in the Pathogenesis of Parkinson's Disease

  2005cited by this paper
• Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: Focused review and a new integrative model

  2005cited by this paper
• Stages in the development of Parkinson’s disease-related pathology

  2004cited by this paper
• Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson’s disease

  2004influential reference
• Staging of brain pathology related to sporadic Parkinson's disease.

  2003cited by this paper
• 5-HT1A receptor knockout mouse as a genetic model of anxiety.

  2003cited by this paper
• Is there a role for 5-HT1A agonists in the treatment of depression?

  2003cited by this paper
• Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. III. Agonist and Antagonist Properties at Serotonin, 5-HT1 and 5-HT2, Receptor Subtypes

  2002cited by this paper
• Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe.

  2002cited by this paper
• Serotonin 5‐HT1A receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys

  2001cited by this paper
• Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease

  2001cited by this paper
• Organization of the basal ganglia: the importance of axonal collateralization.

  2000cited by this paper
• 5‐HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease

  2000cited by this paper
• Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment.

  2000cited by this paper
• Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds.

  2000cited by this paper
• Predictors of Nursing Home Placement in Parkinson's Disease: A Population‐Based, Prospective Study

  2000cited by this paper
• Dopamine D4 Receptor Gene: Novelty or Nonsense?

  1999cited by this paper
• Intravenous levodopa in hallucinating Parkinson's disease patients

  1998influential reference
• Biological profile of L-745,870, a selective antagonist with high affinity for the dopamine D4 receptor.

  1997cited by this paper
• Autoradiographic localization of 5-HT1A receptors in the post-mortem human brain using [3H]WAY-100635 and [11C]way-100635.

  1997cited by this paper
• 5-HT receptors in mammalian brain: receptor autoradiography andin situ hybridization studies of new ligands and newly identified receptors

  1996cited by this paper
• 5-HT1A and 5-HT2A Receptor mRNAs and Binding Site Densities Are Differentially Altered in Schizophrenia

  1996cited by this paper
• The temporal lobe is a target of output from the basal ganglia.

  1996cited by this paper
• WAY-100635, a potent and selective 5-hydroxytryptamine1A antagonist, increases serotonergic neuronal activity in behaving cats: comparison with (S)-WAY-100135.

  1996cited by this paper
• Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine

  1996cited by this paper
• An Improved Approach to Prepare Human Brains for Research

  1995cited by this paper
• WAY100135: a novel, selective antagonist at presynaptic and postsynaptic 5-HT1A receptors.

  1993cited by this paper
• Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration: a positron emission tomography study.

  1993cited by this paper
• Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease

  1990cited by this paper
• NAN-190: agonist and antagonist interactions with brain 5-HT1A receptors.

  1990cited by this paper
• Biochemical pathophysiology of Parkinson's disease.

  1987cited by this paper
• Serotonin receptors in the human brain--III. Autoradiographic mapping of serotonin-1 receptors.

  1987cited by this paper
• Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease.

  1983cited by this paper
• The mysterious motor function of the basal ganglia

  1982cited by this paper
• Receptor basis for dopaminergic supersensitivity in Parkinson's disease

  1978cited by this paper
• Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor.

  1971cited by this paper
• Book Review: Atlas of the Human Brain

  1971cited by this paper
• Parkinsonism

  1967cited by this paper
• Verteilung des 5-Hydroxytryptamins (Serotonin) im Gehirn des Menschen und sein Verhalten bei Patienten mit Parkinson-Syndrom

  1961cited by this paper
• [Distribution of 5-hydroxytryptamine (serotonin) in the human brain and its behavior in patients with Parkinson's syndrome].

  1961cited by this paper

• The effects of chemogenetic targeting of serotonin-projecting pathways on L-DOPA-induced dyskinesia and psychosis in a bilateral rat model of Parkinson’s disease

  2024cites this paper
• Characterizing the relationship between L-DOPA-induced-dyskinesia and psychosis-like behaviors in a bilateral rat model of Parkinson's disease.

  2023cites this paper
• Effect of the mGlu4 positive allosteric modulator ADX-88178 on parkinsonism, psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset

  2023cites this paper
• Emerging role of psychosis in Parkinson's disease: From clinical relevance to molecular mechanisms

  2022cites this paper
• The effect of 5‐HT1A receptor agonists on the entopeduncular nucleus is modified in 6‐hydroxydopamine‐lesioned rats

  2021cites this paper
• Different Alterations of Agonist and Antagonist Binding to 5-HT1A Receptor in a Rat Model of Parkinson’s Disease and Levodopa-Induced Dyskinesia: A MicroPET Study

  2021influential citation
• Serotonin in Parkinson's disease

  2020cites this paper
• Dysfunction of serotonergic neurons in Parkinson's disease and dyskinesia.

  2019cites this paper
• Presynaptic dopaminergic terminal imaging and non-motor symptoms assessment of Parkinson’s disease: evidence for dopaminergic basis?

  2017cites this paper
• Psychosis in Parkinson's Disease.

  2017cites this paper
• Serotonergic Approaches in Parkinson's Disease: Translational Perspectives, an Update.

  2017cites this paper
• Caractérisation neurochimique de la dyskinésie tardive dans un modèle primate non humain

  2017cites this paper
• Imaging the Nonmotor Symptoms in Parkinson's Disease.

  2017cites this paper
• The psychosis spectrum in Parkinson disease

  2017cites this paper
• Imaging Dopamine and Serotonin Systems on MPTP Monkeys: A Longitudinal PET Investigation of Compensatory Mechanisms

  2016cites this paper
• Associations between plasma ceramides and cognitive and neuropsychiatric manifestations in Parkinson's disease dementia.

  2016cites this paper
• 5-HT1A receptor-dependent control of nigrostriatal dopamine neurotransmission in the pharmacotherapy of Parkinson's disease and schizophrenia.

  2015cites this paper
• Vers l'imagerie in vivo de l'alpha-synucléine.

  2015cites this paper
• Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations.

  2014cites this paper
• Reduction of Parkinsonism and Psychosis with Mirtazapine: A Case Report

  2014cites this paper
• Interaction between the 5-HT system and the basal ganglia: functional implication and therapeutic perspective in Parkinson's disease

  2014cites this paper
• Sistema serotonergikoaren eta gongoil basalen arteko elkarrekintza: inplikazio funtzionala eta terapiaren alderdia Parkinsonen gaixotasunean

  2014cites this paper
• Serotonergic nerve fibers in L-DOPA-derived dopamine release and dyskinesia.

  2014cites this paper
• Therapies under investigation for treating Parkinson's disease psychosis

  2014cites this paper
• Deficits in Striatal Dopamine and Hippocampal Serotonin Following Induction of Anxiety/Depressive-Like Behaviors by Bisphenol A

  2014cites this paper
• Improving the Treatment of Parkinson's Disease: A Novel Approach by Modulating 5-HT(1A) Receptors.

  2013cites this paper
• Effects of 5-HT1A receptor stimulation on D1 receptor agonist-induced striatonigral activity and dyskinesia in hemiparkinsonian rats.

  2013cites this paper
• The serotonergic system in motor and non-motor manifestations of Parkinson’s disease

  2013cites this paper
• Effect of chronic l-DOPA treatment on 5-HT(1A) receptors in parkinsonian monkey brain.

  2012cites this paper